C. Schmidt-Gersbach

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

J. Wood, J. Pinheiro, J. Drevs, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Receptor tyrosine kinases: the main targets for new anticancer therapy.

J. Drevs, C. Unger, M. Medinger, 2003, Current drug targets.

Antiangiogenesis: Current Clinical Data and Future Perspectives

J. Drevs, C. Unger, M. Medinger, 2002, Oncology Research and Treatment.

Angiogenesis and the ET-1/ETA Receptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors

J. Drevs, C. Unger, C. Adler, 2004, Angiogenesis.

Receptor tyrosine kinases: the main targets for new anticancer therapy.

J. Drevs, C. Unger, M. Medinger, 2003, Current Drug Targets.

Contents of Next Issues · Themenvorschau

J. Drevs, D. Strumberg, U. Massing, 2002, Oncology Research and Treatment.